Hub : Traits :

Heart attack

45 significantly associated models · 14 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	109098737	110517617	3	1	6.2e-09	5.2e-09	1.0e+00	100	PSRC1
2	1	222096959	223567803	3	1	1.1e-11	1.4e-11	1.0e+00	100	RP11-378J18.8
3	6	12020241	13990267	2	1	5.0e-16	5.4e-16	4.7e-02	94	RP1-257A7.5
4	6	159820779	161571560	3	3	5.1e-09	8.9e-12	3.9e-05	64	RP11-288H12.3 SLC22A1 SLC22A3
5	9	21303958	22819407	2	2	1.7e-15	1.1e-30	1.5e-15	52	CDKN2B CDKN2B-AS1
6	15	90730363	92135418	1	1	3.3e-08	9.0e-07	9.2e-01	100	FES

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
LDL Cholesterol	63.99	2	1	2.2	0.00	1.0e+00	PSRC1 RP11-288H12.3
Heart attack/myocardial infarction (self-reported)	34.16	9	9	20.0	1.00	2.6e-13	CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-378J18.8 RP1-257A7.5 SLC22A1 SLC22A3
Angina (self-reported)	33.17	9	6	13.3	0.97	2.0e-05	CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-378J18.8 RP1-257A7.5 SLC22A1 SLC22A3
High cholesterol (Self-reported)	32.87	6	4	8.9	0.78	6.5e-02	FES PSRC1 RP11-288H12.3 RP11-378J18.8 SLC22A1 SLC22A3
Illnesses of father: Heart disease	32.77	9	7	15.6	0.97	1.8e-05	CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-378J18.8 RP1-257A7.5 SLC22A1 SLC22A3
Angina	31.83	9	6	13.3	0.97	2.5e-05	CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-378J18.8 RP1-257A7.5 SLC22A1 SLC22A3
Coronary Artery Disease (CAD)	31.37	5	4	8.9	0.99	1.6e-03	CDKN2B CDKN2B-AS1 PSRC1 RP1-257A7.5 SLC22A3
Medication: Cholesterol lowering	31.03	8	4	8.9	0.89	3.4e-03	CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-378J18.8 SLC22A1 SLC22A3
Medication: Atorvastatin	22.46	6	3	6.7	0.96	2.1e-03	CDKN2B CDKN2B-AS1 PSRC1 RP11-288H12.3 SLC22A1 SLC22A3
Medication: Simvastatin	19.96	6	2	4.4	0.90	1.4e-02	CDKN2B CDKN2B-AS1 FES PSRC1 SLC22A1 SLC22A3
Medication: Aspirin	18.75	7	5	11.1	0.99	5.2e-06	CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 SLC22A1 SLC22A3
Medication: Aspirin	18.09	7	5	11.1	0.99	1.4e-05	CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 SLC22A1 SLC22A3
Heart disease (mother)	17.65	8	3	6.7	0.96	2.1e-04	CDKN2B CDKN2B-AS1 FES RP11-288H12.3 RP11-378J18.8 RP1-257A7.5 SLC22A1 SLC22A3
Cholesterol lowering medication	17.44	5	2	4.4	0.90	4.0e-02	CDKN2B PSRC1 RP11-288H12.3 SLC22A1 SLC22A3
Medication for cholesterol, blood pressure or diabetes	14.66	4	2	4.4	0.50	5.0e-01	FES PSRC1 RP11-378J18.8 SLC22A1
Heart disease (siblings)	13.63	8	0	0.0	0.97	1.0e-04	CDKN2B CDKN2B-AS1 FES PSRC1 RP11-378J18.8 RP1-257A7.5 SLC22A1 SLC22A3
Illnesses of father: None of the above (group 1)	12.03	4	2	4.4	-0.99	5.1e-03	CDKN2B CDKN2B-AS1 FES SLC22A3
Cardiovascular Disease	11.20	5	3	6.7	0.96	9.3e-03	FES PSRC1 RP11-288H12.3 SLC22A1 SLC22A3
Vascular/heart problems diagnosed by doctor	9.88	3	1	2.2	0.00	1.0e+00	CDKN2B FES SLC22A3
Eye problems/disorders: Glaucoma	9.20	2	2	4.4	0.00	1.0e+00	CDKN2B CDKN2B-AS1
High blood pressure (mother)	8.84	2	1	2.2	0.00	1.0e+00	FES RP1-257A7.5
Father's age at death	8.67	4	1	2.2	-1.00	2.7e-03	CDKN2B CDKN2B-AS1 FES PSRC1
Hypertension (Self-reported)	8.31	3	1	2.2	0.00	1.0e+00	FES RP1-257A7.5 SLC22A3
High blood pressure	8.04	2	1	2.2	0.00	1.0e+00	FES RP1-257A7.5
Systolic Blood Pressure	8.03	4	2	4.4	0.26	7.4e-01	FES RP1-257A7.5 SLC22A1 SLC22A3
Medication: Blood pressure	7.92	2	1	2.2	0.00	1.0e+00	FES SLC22A1
Medication: Atenolol	7.90	2	1	2.2	0.00	1.0e+00	CDKN2B FES
Medication for cholesterol	7.44	3	1	2.2	0.00	1.0e+00	FES PSRC1 SLC22A3
Glaucoma (self-reported)	7.33	2	1	2.2	0.00	1.0e+00	CDKN2B CDKN2B-AS1
Systolic blood pressure, automated reading	6.98	2	2	4.4	0.00	1.0e+00	FES RP1-257A7.5
Illnesses of mother	6.82	2	1	2.2	0.00	1.0e+00	CDKN2B FES
Medication: Blood pressure	6.59	2	1	2.2	0.00	1.0e+00	FES SLC22A3
Diastolic blood pressure, automated reading	6.26	3	1	2.2	0.00	1.0e+00	CDKN2B CDKN2B-AS1 FES
Medication: Ramipril	6.03	2	0	0.0	0.00	1.0e+00	FES SLC22A3
Illnesses of father: High blood pressure	5.97	1	1	2.2	0.00	1.0e+00	FES
Headache pain in last month	5.76	2	1	2.2	0.00	1.0e+00	FES RP1-257A7.5
Migraine (self-reported)	5.75	1	1	2.2	0.00	1.0e+00	RP1-257A7.5
Pulse wave Arterial Stiffness index	4.84	2	0	0.0	0.00	1.0e+00	FES RP1-257A7.5
Pulse wave peak to peak time	4.75	2	0	0.0	0.00	1.0e+00	FES RP1-257A7.5
Medication: Ibuprofen (e.g. Nurofen)	4.70	2	1	2.2	0.00	1.0e+00	RP1-257A7.5 SLC22A3
Medication: Ibuprofen	4.70	2	0	0.0	0.00	1.0e+00	RP1-257A7.5 SLC22A3
Birth weight of first child	4.65	1	1	2.2	0.00	1.0e+00	FES
Number of treatments/medications taken	4.35	2	0	0.0	0.00	1.0e+00	FES PSRC1
Illnesses of siblings	4.00	1	1	2.2	0.00	1.0e+00	FES
High blood pressure (siblings)	3.84	1	1	2.2	0.00	1.0e+00	FES
Medication for pain relief, constipation, heartburn	3.67	3	0	0.0	0.00	1.0e+00	PSRC1 RP1-257A7.5 SLC22A1
Bipolar Disorder or Schizophrenia	3.65	1	1	2.2	0.00	1.0e+00	FES
Schizophrenia (2018)	3.59	1	1	2.2	0.00	1.0e+00	FES
Medication: Amlodipine	3.55	1	1	2.2	0.00	1.0e+00	FES
Chest pain or discomfort	3.53	1	0	0.0	0.00	1.0e+00	CDKN2B
Number of self-reported non-cancer illnesses	3.37	1	0	0.0	0.00	1.0e+00	PSRC1
Basal cell carcinoma (self-reported)	3.34	1	0	0.0	0.00	1.0e+00	CDKN2B
Schizophrenia (2014)	3.27	1	1	2.2	0.00	1.0e+00	FES
Medication: Bendroflumethiazide	3.16	1	1	2.2	0.00	1.0e+00	FES
Past tobacco smoking	3.15	1	0	0.0	0.00	1.0e+00	CDKN2B-AS1
Supplements: Fish oil (including cod liver oil)	3.02	1	0	0.0	0.00	1.0e+00	SLC22A3
Breast Cancer	3.01	3	0	0.0	0.00	1.0e+00	CDKN2B CDKN2B-AS1 FES
Type 2 Diabetes (T2D) (2012)	2.96	1	0	0.0	0.00	1.0e+00	CDKN2B
Smoking status: Previous	2.86	1	0	0.0	0.00	1.0e+00	CDKN2B-AS1
HDL Cholesterol	2.84	1	1	2.2	0.00	1.0e+00	PSRC1
Risk taking	2.82	1	0	0.0	0.00	1.0e+00	FES
Birth weight	2.80	1	1	2.2	0.00	1.0e+00	FES
Mother's age at death	2.79	1	0	0.0	0.00	1.0e+00	SLC22A1
Smoking Status	2.66	1	0	0.0	0.00	1.0e+00	FES
Mineral and other dietary supplements	2.60	1	0	0.0	0.00	1.0e+00	FES
Breast cancer (self-reported)	2.59	1	0	0.0	0.00	1.0e+00	CDKN2B
Ever smoked	2.57	1	0	0.0	0.00	1.0e+00	FES
Medication: Paracetamol	2.56	1	1	2.2	0.00	1.0e+00	RP1-257A7.5
Waist Hip Ratio (WHR)	2.53	3	1	2.2	0.00	1.0e+00	RP11-288H12.3 RP11-378J18.8 SLC22A3
Triglycerides	2.36	1	0	0.0	0.00	1.0e+00	RP11-288H12.3
Hand grip strength (left)	2.25	2	0	0.0	0.00	1.0e+00	FES RP1-257A7.5
Medication: Lisinopril	2.25	1	0	0.0	0.00	1.0e+00	FES
Sensitivity / hurt feelings	2.19	1	1	2.2	0.00	1.0e+00	FES
Medication: Metformin	2.15	1	0	0.0	0.00	1.0e+00	CDKN2B
Alcohol intake frequency.	2.05	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Pulse rate	1.94	1	0	0.0	0.00	1.0e+00	SLC22A1
Hand grip strength (right)	1.91	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Breastfed as a baby	1.91	1	0	0.0	0.00	1.0e+00	FES
Hearing difficulty/problems: Yes	1.88	1	0	0.0	0.00	1.0e+00	RP11-378J18.8
Long-standing illness, disability or infirmity	1.87	1	0	0.0	0.00	1.0e+00	CDKN2B
Pain experienced in last month	1.83	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Bipolar Disorder (2018)	1.79	1	0	0.0	0.00	1.0e+00	FES
Alcohol usually taken with meals	1.78	1	0	0.0	0.00	1.0e+00	FES
Pulse rate, automated reading	1.78	2	0	0.0	0.00	1.0e+00	RP11-378J18.8 RP1-257A7.5
Number of incorrect matches in round	1.77	1	0	0.0	0.00	1.0e+00	FES
Neuroticism	1.74	3	0	0.0	0.00	1.0e+00	FES RP1-257A7.5 SLC22A1
Type 2 Diabetes (T2D) (2018)	1.72	1	0	0.0	0.00	1.0e+00	SLC22A3
Neuroticism (Nagel 2018)	1.71	2	0	0.0	0.00	1.0e+00	FES SLC22A1
Mean time to correctly identify matches	1.70	1	0	0.0	0.00	1.0e+00	FES
Impedance of leg (right)	1.69	2	1	2.2	0.00	1.0e+00	FES RP11-378J18.8
Medication: Paracetamol	1.69	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Allergy	1.63	1	0	0.0	0.00	1.0e+00	FES
Respiratory disease	1.62	1	0	0.0	0.00	1.0e+00	FES
Trunk fat mass	1.59	2	0	0.0	0.00	1.0e+00	RP1-257A7.5 SLC22A3
Trunk fat percentage	1.56	2	0	0.0	0.00	1.0e+00	RP1-257A7.5 SLC22A3
Handedness (chirality/laterality): Left-handed	1.54	1	0	0.0	0.00	1.0e+00	FES
Diabetes diagnosed by doctor	1.54	1	0	0.0	0.00	1.0e+00	SLC22A3
Leg predicted mass (right)	1.52	3	0	0.0	0.00	1.0e+00	FES PSRC1 SLC22A3
Whole body fat mass	1.51	2	0	0.0	0.00	1.0e+00	RP1-257A7.5 SLC22A3
Arm fat percentage (right)	1.49	2	0	0.0	0.00	1.0e+00	RP1-257A7.5 SLC22A3
Hair/balding pattern: Pattern 4	1.49	1	0	0.0	0.00	1.0e+00	FES
Body fat percentage	1.49	2	0	0.0	0.00	1.0e+00	RP1-257A7.5 SLC22A3
Leg fat-free mass (right)	1.49	3	0	0.0	0.00	1.0e+00	FES PSRC1 SLC22A3
Impedance of leg (left)	1.48	2	1	2.2	0.00	1.0e+00	FES RP11-378J18.8
Hip circumference	1.48	1	1	2.2	0.00	1.0e+00	SLC22A3
Average weekly champagne plus white wine intake	1.48	1	0	0.0	0.00	1.0e+00	RP11-288H12.3
Lung FEV1/FVC ratio	1.47	2	2	4.4	0.00	1.0e+00	PSRC1 RP11-378J18.8
Allergy or Eczema	1.45	1	0	0.0	0.00	1.0e+00	FES
Hayfever, allergic rhinitis or eczema	1.45	1	0	0.0	0.00	1.0e+00	FES
Worry (Nagel 2018)	1.44	1	0	0.0	0.00	1.0e+00	SLC22A1
Leg predicted mass (left)	1.44	3	0	0.0	0.00	1.0e+00	FES PSRC1 SLC22A3
Leg fat-free mass (left)	1.43	3	0	0.0	0.00	1.0e+00	FES PSRC1 SLC22A3
Arm fat mass (right)	1.39	2	0	0.0	0.00	1.0e+00	RP1-257A7.5 SLC22A3
Leg fat percentage (right)	1.38	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Arm fat mass (left)	1.37	2	0	0.0	0.00	1.0e+00	RP1-257A7.5 SLC22A3
Knee pain experienced in last month	1.36	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Arm fat percentage (left)	1.35	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Whole body fat-free mass	1.34	3	0	0.0	0.00	1.0e+00	FES PSRC1 SLC22A3
Weight	1.32	2	0	0.0	0.00	1.0e+00	RP1-257A7.5 SLC22A3
Basal metabolic rate	1.32	3	0	0.0	0.00	1.0e+00	FES PSRC1 SLC22A3
Age started oral contraceptive pill	1.32	1	0	0.0	0.00	1.0e+00	FES
Whole body water mass	1.31	3	0	0.0	0.00	1.0e+00	FES PSRC1 SLC22A3
Trunk fat-free mass	1.30	2	1	2.2	0.00	1.0e+00	PSRC1 SLC22A3
Trunk predicted mass	1.28	2	1	2.2	0.00	1.0e+00	PSRC1 SLC22A3
Comparative height size at age 10	1.25	3	0	0.0	0.00	1.0e+00	FES PSRC1 SLC22A3
Blood White Count	1.24	3	1	2.2	0.00	1.0e+00	CDKN2B FES RP1-257A7.5
Arm predicted mass (right)	1.22	2	0	0.0	0.00	1.0e+00	PSRC1 SLC22A3
Asthma	1.18	1	0	0.0	0.00	1.0e+00	FES
Asthma (self-reported)	1.18	1	0	0.0	0.00	1.0e+00	FES
Arm predicted mass (left)	1.18	2	0	0.0	0.00	1.0e+00	PSRC1 SLC22A3
Leg fat mass (right)	1.17	2	0	0.0	0.00	1.0e+00	RP1-257A7.5 SLC22A3
Arm fat-free mass (right)	1.15	2	0	0.0	0.00	1.0e+00	PSRC1 SLC22A3
Leg fat percentage (left)	1.14	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Other serious medical condition/disability diagnosed by doctor	1.12	1	0	0.0	0.00	1.0e+00	PSRC1
Crohns Disease (2017)	1.11	1	0	0.0	0.00	1.0e+00	FES
BMI	1.11	2	0	0.0	0.00	1.0e+00	RP1-257A7.5 SLC22A3
Arm fat-free mass (left)	1.07	2	0	0.0	0.00	1.0e+00	PSRC1 SLC22A3
Leg fat mass (left)	1.07	2	0	0.0	0.00	1.0e+00	RP1-257A7.5 SLC22A3
Number of live births	1.05	1	0	0.0	0.00	1.0e+00	FES
Height	1.01	4	4	8.9	-0.99	5.7e-03	FES PSRC1 RP11-288H12.3 SLC22A3
Standing height	1.01	3	1	2.2	0.00	1.0e+00	PSRC1 RP11-288H12.3 SLC22A3
Qualifications: College or University degree	0.94	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Impedance of whole body	0.90	2	0	0.0	0.00	1.0e+00	FES PSRC1
Sitting height	0.89	2	0	0.0	0.00	1.0e+00	FES SLC22A3
Impedance of arm (right)	0.86	1	0	0.0	0.00	1.0e+00	CDKN2B
Waist circumference	0.81	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Lung FVC	0.76	1	0	0.0	0.00	1.0e+00	RP11-378J18.8
Body mass index (BMI)	0.71	1	0	0.0	0.00	1.0e+00	RP1-257A7.5
Blood Red Count	0.63	2	0	0.0	0.00	1.0e+00	FES RP1-257A7.5
Hair Pigment	0.61	3	3	6.7	0.00	1.0e+00	CDKN2B CDKN2B-AS1 FES
Blood Platelet Count	0.53	2	0	0.0	0.00	1.0e+00	CDKN2B SLC22A3
Heel T-Score	0.50	1	0	0.0	0.00	1.0e+00	PSRC1

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Artery Aorta	3	0.101	1.4
GTEx	Artery Coronary	1	0.085	1.4
GTEx	Artery Tibial	4	0.106	1.4
GTEx	Brain Cerebellum	1	0.050	1.4
GTEx	Spleen	0	0.000	1.4
GTEx	Stomach	0	0.000	1.4
GTEx	Vagina	0	0.000	1.4
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	0	0.000	1.4
GTEx	Adipose Subcutaneous	1	0.029	1.3
GTEx	Adipose Visceral Omentum	0	0.000	1.3
GTEx	Adrenal Gland	0	0.000	1.3
GTEx	Brain Caudate basal ganglia	0	0.000	1.3
GTEx	Brain Cerebellar Hemisphere	2	0.134	1.3
GTEx	Brain Frontal Cortex BA9	0	0.000	1.3
GTEx	Brain Hypothalamus	1	0.169	1.3
GTEx	Brain Putamen basal ganglia	0	0.000	1.3
GTEx	Breast Mammary Tissue	1	0.051	1.3
GTEx	Breast Mammary Tissue (Male)	0	0.000	1.3
GTEx	Cells Transformed fibroblasts	3	0.071	1.3
GTEx	Colon Sigmoid	1	0.068	1.3
GTEx	Colon Transverse	0	0.000	1.3
GTEx	Esophagus Gastroesophageal Junction	1	0.069	1.3
GTEx	Esophagus Mucosa	1	0.030	1.3
GTEx	Esophagus Muscularis	2	0.062	1.3
GTEx	Heart Atrial Appendage	0	0.000	1.3
GTEx	Heart Left Ventricle	0	0.000	1.3
GTEx	Liver	1	0.139	1.3
GTEx	Lung	1	0.035	1.3
GTEx	Muscle Skeletal	1	0.035	1.3
GTEx	Nerve Tibial	2	0.046	1.3
GTEx	Ovary	1	0.110	1.3
GTEx	Pancreas	0	0.000	1.3
GTEx	Pituitary	0	0.000	1.3
GTEx	Prostate	1	0.120	1.3
GTEx	Skin Not Sun Exposed Suprapubic	0	0.000	1.3
GTEx	Skin Sun Exposed Lower leg	1	0.027	1.3
GTEx	Small Intestine Terminal Ileum	0	0.000	1.3
GTEx	Thyroid	0	0.000	1.3
GTEx	Uterus	0	0.000	1.3
GTEx	Whole Blood	1	0.050	1.3
METSIM	Adipose	0	0.000	1.3
NTR	Blood	0	0.000	1.3
ROSMAP	Brain Pre-frontal Cortex	1	0.023	1.3
CommonMind	Brain Pre-frontal Cortex	3	0.056	1.3
The Cancer Genome Atlas	Breast Invasive Carcinoma	2	0.045	1.3
The Cancer Genome Atlas	Colon Adenocarcinoma	0	0.000	1.3
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	1	0.024	1.3
The Cancer Genome Atlas	Brain Lower Grade Glioma	2	0.046	1.3
The Cancer Genome Atlas	Lung Adenocarcinoma	0	0.000	1.3
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	0	0.000	1.3
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	0	0.000	1.3
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.3
The Cancer Genome Atlas	Stomach Adenocarcinoma	0	0.000	1.3
The Cancer Genome Atlas	Thyroid Carcinoma	1	0.019	1.3
GTEx	Brain Cortex	0	0.000	1.2
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.2
GTEx	Breast Mammary Tissue (Female)	1	0.061	1.2
GTEx	Cells EBV-transformed lymphocytes	0	0.000	1.2
GTEx	Testis	0	0.000	1.2
YFS	Blood	0	0.000	1.2
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	0	0.000	1.2
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	0	0.000	1.2
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	1.2
The Cancer Genome Atlas	Glioblastoma Multiforme	0	0.000	1.2
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	0	0.000	1.2
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	1	0.049	1.2
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	2	0.181	1.2
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	0	0.000	1.2
The Cancer Genome Atlas	Prostate Adenocarcinoma	0	0.000	1.2
The Cancer Genome Atlas	Rectum Adenocarcinoma	0	0.000	1.2
The Cancer Genome Atlas	Soft Tissue Sarcoma	0	0.000	1.2
The Cancer Genome Atlas	Testicular Germ Cell Tumors	0	0.000	1.2
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.2
GTEx	Brain Hippocampus	0	0.000	1.1